Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Investments (2019 - 2025)

Fate Therapeutics (FATE) has disclosed Long-Term Investments for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 94.68% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, down 94.68%, and an annual FY2025 reading of $1.5 million, down 94.68% over the prior year.
  • Long-Term Investments was $1.5 million for Q4 2025 at Fate Therapeutics, down from $10.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $149.5 million in Q2 2021 and bottomed at $980000.0 in Q4 2023.
  • Average Long-Term Investments over 5 years is $40.5 million, with a median of $26.1 million recorded in 2025.
  • The sharpest move saw Long-Term Investments tumbled 95.09% in 2022, then surged 2722.14% in 2024.
  • Year by year, Long-Term Investments stood at $100.7 million in 2021, then crashed by 95.09% to $4.9 million in 2022, then crashed by 80.17% to $980000.0 in 2023, then soared by 2722.14% to $27.7 million in 2024, then tumbled by 94.68% to $1.5 million in 2025.
  • Business Quant data shows Long-Term Investments for FATE at $1.5 million in Q4 2025, $10.3 million in Q3 2025, and $26.1 million in Q2 2025.